Clinical development failure
The company has not yet demonstrated success in pivotal trials or commercial approval, so negative Phase 3 results would materially reduce value.
- Scope
- Descartes-08 and future pipeline programs
- Materiality
- high
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA-based cell therapies for autoimmune diseases. The company’s most advanced program is Descartes-08, an autologous cell therapy in Phase 3 development for myasthenia gravis. Cartesian was formed through a 2023 merger that combined the current public company with the former Cartesian Therapeutics business and is headquartered in Frederick, Maryland. It does not yet sell approved products and currently relies on collaboration revenue, grant funding, and capital markets financing to support research and development.
−5 041,3 %
−4 658,6 %
−92,8 %
8.65
8.65
| % | |
|---|---|
| Clinical-stage cell therapy candidates | 0% Autologous mRNA-based cell therapy programs in clinical development, including Descartes-08. |
| Collaboration and license revenue | 65% Upfront, milestone, and other payments recognized under partnering and licensing agreements. |
| Grant revenue | 35% Funding received to perform specified research and development services under grant arrangements. |
| Out-licensed assets | 0% Licensed programs such as Xork that may generate upfront, milestone, or royalty economics. |
Cartesian’s direct customers are not patients in the commercial sense today; instead, its revenue comes mainly from...
- Pharmaceutical collaboration partnersprimary
Companies such as Astellas that license programs or rights and pay for development and commercialization access.
- Grant funding organizationssecondary
Public or private grant providers that reimburse defined research and development activities.
- Future autoimmune disease prescribersemerging
Physicians and specialty centers that would prescribe or administer Descartes-08 if approved, based on efficacy and safety.
- Third-party payorsemerging
Insurers and reimbursement bodies that would determine access and commercial uptake for any approved therapy.
Cartesian is headquartered in Frederick, Maryland and operates primarily from the United States...
- •Headquartered in Frederick, Maryland, United States
- •Clinical development and regulatory activity are centered in the U.S.
- •Future commercialization is expected to begin in the United States if approved
- •Competition and scientific benchmarking are global, but operations are U.S.-focused
- •Consolidated structure includes a Russian subsidiary, though not a disclosed revenue market
Cartesian’s strategy is to advance Descartes-08 through late-stage clinical development and position its mRNA cell...
01
Complete late-stage development of Descartes-08short-term
The company’s value creation depends on proving clinical efficacy, safety, and durability in myasthenia gravis.
02
Secure non-dilutive and partnership fundingshort-term
The business remains pre-commercial and needs external capital to finance trials and manufacturing.
03
Build a scalable manufacturing and regulatory pathwaymedium-term
Autologous cell therapy requires reliable patient-by-patient manufacturing and regulatory compliance.
Cartesian faces the classic risks of a clinical-stage biotech company, including clinical failure, regulatory delay,...
Manufacturing and logistics complexity
Autologous cell therapies are made patient-by-patient and are harder to scale, increasing the risk of delays, shortages, or quality issues.
- Scope
- Internal manufacturing and third-party testing
- Materiality
- high
Financing and dilution risk
The company is pre-commercial and may need additional equity or debt financing before product revenue arrives.
- Scope
- Operating runway and development funding
- Materiality
- high
Commercial adoption and reimbursement risk
Even if approved, physicians and payors may prefer established or cheaper alternatives, limiting uptake.
- Scope
- Future myasthenia gravis market entry
- Materiality
- medium
Competitive pressure from larger biotech and pharma companies
Competitors may develop more effective or faster-to-market therapies with greater resources.
- Scope
- Autoimmune disease and CAR-T/cell therapy markets
- Materiality
- medium
Collaboration and license revenue recognition
Astellas termination caused a sharp reduction in recognized collaboration revenue
Grant revenue recognition
Creates uneven quarterly revenue and affects comparability
Fair value liabilities
Can materially distort net loss or income independent of operations
Research and development expense capitalization policy
Higher trial activity increases operating loss immediately
: 28.4.2026